{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T12:45:17Z","timestamp":1794055517636,"version":"4.8.0"},"reference-count":10,"publisher":"Centers for Disease Control MMWR Office","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["MMWR Morb. Mortal. Wkly. Rep."],"DOI":"10.15585\/mmwr.mm7004e1","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T15:37:35Z","timestamp":1611329855000},"page":"125-129","source":"Crossref","is-referenced-by-count":233,"title":["Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine \u2014 United States, December 21, 2020\u2013January 10, 2021"],"prefix":"10.15585","volume":"70","author":[{"name":"CDC COVID-19 Response Team","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Food and Drug Administration","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6224","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R1","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.15585\/mmwr.mm695152e1","article-title":"The Advisory Committee on Immunization Practices\u2019 interim recommendation for use of Moderna COVID-19 vaccine\u2014United States, December 2020.","volume":"69","author":"Oliver","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R2","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.jaci.2017.12.971","article-title":"Vaccine-associated hypersensitivity.","volume":"141","author":"McNeil","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R3","unstructured":"CDC. COVID-19 vaccination: clinical considerations. Interim clinical considerations for use of mRNA COVID-19 vaccines currently authorized in the United States. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https:\/\/www.cdc.gov\/vaccines\/covid-19\/info-by-product\/clinical-considerations.html"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R4","unstructured":"CDC. COVID-19 vaccination: clinical considerations. Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/managing-anaphylaxis.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fcovid-19%2Finfo-by-product%2Fpfizer%2Fanaphylaxis-management.html"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.15585\/mmwr.mm7002e1","article-title":"Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine\u2014United States, December 14\u201323, 2020.","volume":"70","author":"CDC COVID-19 Response Team","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R6","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R7","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data.","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R8","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990\u20132016.","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R9","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.2105\/AJPH.85.12.1706","article-title":"The reporting sensitivities of two passive surveillance systems for vaccine adverse events.","volume":"85","author":"Rosenthal","year":"1995","journal-title":"Am J Public Health"},{"key":"key-10.15585\/mmwr.mm7004e1-202101281058-R10","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.15585\/mmwr.mm6942e2","article-title":"Excess deaths associated with COVID-19, by age and race and ethnicity\u2014United States, January 26\u2013October 3, 2020.","volume":"69","author":"Rossen","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["MMWR. Morbidity and Mortality Weekly Report"],"original-title":[],"deposited":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T16:42:43Z","timestamp":1611852163000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cdc.gov\/mmwr\/volumes\/70\/wr\/mm7004e1.htm?s_cid=mm7004e1_w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,1,29]]}},"URL":"https:\/\/doi.org\/10.15585\/mmwr.mm7004e1","relation":{},"ISSN":["0149-2195","1545-861X"],"issn-type":[{"value":"0149-2195","type":"print"},{"value":"1545-861X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,29]]},"published":{"date-parts":[[2021,1,29]]}}}